Background Entecavir is a potent and selective antiviral agent that has demonstrated efficacy in phase 2 studies in patients with hepatitis B e antigen (HBeAg)-negative chronic hepatitis B.Methods In this phase 3, double-blind trial, we randomly assigned 648 patients with HBeAg-negative chronic hepa...
Research Assistant
AI chat, annotations, notes & similar papers
No comments yet
Be the first to share your thoughts!